DGIdb - HLA-B Gene Record

HLA-B 3106 Druggable Genome

Alternate Names:

3106
MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS I, B
HLA-B
AS
B-4901
HLAB
142830
4932
ENSG00000234745
OTTHUMG00000031153
PA35056
HLA class I antigen B-7
T47415

Gene Info:

Gene Biotype	PROTEIN_CODING

(4 More Sources)

Gene Categories: Category Details

CELL SURFACE
DRUGGABLE GENOME

Publications:

Xu CF et al., 2016, HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer., Clin Cancer Res
Cai F et al., 2018, Dapsone-induced drug reaction with eosinophilia and systemic symptoms associated with HLA-B*13:01., Intern Med J
Chen WT et al., 2018, The Function of HLA-B*13:01 Involved in the Pathomechanism of Dapsone-Induced Severe Cutaneous Adverse Reactions., J Invest Dermatol
Tempark T et al., 2017, Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population., Pharmacogenet Genomics
Zhang FR et al., 2013, HLA-B*13:01 and the dapsone hypersensitivity syndrome., N Engl J Med
Wang H et al., 2013, Association between HLA-B*1301 and dapsone-induced hypersensitivity reactions among leprosy patients in China., J Invest Dermatol
Murata et al., 2004, Reiter's syndrome following intravesical bacille biliE de Calmette-GuErin treatment for superficial bladder carcinoma: report of six cases., Mod Rheumatol
Hirata K et al., 2008, Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study., Pharmacogenomics J
Valevski A et al., 1998, HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients., Eur J Immunogenet
Saito T et al., 2016, Pharmacogenomic Study of Clozapine-Induced Agranulocytosis/Granulocytopenia in a Japanese Population., Biol Psychiatry
Lieberman JA et al., 1990, HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia., Arch Gen Psychiatry
Romero-Gómez M et al., 2003, HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C., Am J Gastroenterol
Farag RE et al., 2013, Human leukocyte antigen class I alleles can predict response to pegylated interferon/ribavirin therapy in chronic hepatitis C Egyptian patients., Arch Iran Med
Alfirevic et al., 2006, HLA-B locus in Caucasian patients with carbamazepine hypersensitivity., Pharmacogenomics
Yang L et al., 2009, Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome., PLoS Comput Biol
Cheung CL et al., 2016, HLA-B*38:02:01 predicts carbimazole/methimazole-induced agranulocytosis., Clin Pharmacol Ther
Chen PL et al., 2015, Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study., Nat Commun
Cirulli ET et al., 2019, A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury., Gastroenterology
Her Y et al., 2011, Stevens-Johnson syndrome induced by acetazolamide., J Dermatol
Shannon et al., 1994, Thalidomide does not perturb CD2, CD4, CD5, CD8, HLA-DR, or HLA-A, B, C molecules in vitro on the membranes of cells with immune potential., Immunopharmacol Immunotoxicol
Mallal S et al., 2008, HLA-B*5701 screening for hypersensitivity to abacavir., N Engl J Med
Wuillemin N et al., 2014, T cells infiltrate the liver and kill hepatocytes in HLA-B(∗)57:01-associated floxacillin-induced liver injury., Am J Pathol
Wuillemin N et al., 2013, HLA haplotype determines hapten or p-i T cell reactivity to flucloxacillin., J Immunol
Phillips EJ et al., 2013, HLA-B*5701 and flucloxacillin associated drug-induced liver disease., AIDS
Yip VL et al., 2012, HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review., Clin Pharmacol Ther
Vera JH et al., 2013, The safety of flucloxacillin in HIV-infected patients with positive HLA-B*5701 genotype., AIDS
Tassaneeyakul W et al., 2009, Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population., Pharmacogenet Genomics
Daly AK et al., 2009, HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin., Nat Genet
Locharernkul C et al., 2008, Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population., Epilepsia
Yang F et al., 2014, HLA-B*13:01 is associated with salazosulfapyridine-induced drug rash with eosinophilia and systemic symptoms in Chinese Han population., Pharmacogenomics
Tangamornsuksan W et al., 2019, Association between HLA-B*5901 and methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis., Pharmacogenomics J
Shu C et al., 2015, Toxic epidermal necrolysis induced by methazolamide in a Chinese-Korean man carrying HLA-B*59:01., Int J Dermatol
Yang F et al., 2016, HLA-B*59:01: a marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese., Pharmacogenomics J
Kim SH et al., 2010, HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis., Pharmacogenomics
Shirato S et al., 1997, Stevens-Johnson syndrome induced by methazolamide treatment., Arch Ophthalmol
Yang Y et al., 2017, HLA-B*51:01 is strongly associated with clindamycin-related cutaneous adverse drug reactions., Pharmacogenomics J

FLOXACILLIN HLA-B

Interaction Score: 3.89

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30664875 18256392 24731753 23596311 23291545 23132554 23032409 19696695 19483685 18637831

Sources:
PharmGKB
TRICHLOROETHYLENE HLA-B

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FOSPHENYTOIN HLA-B

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
METHAZOLAMIDE HLA-B

Interaction Score: 1.85

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30242287 25970075 25918017 20504258 9109770

Sources:
PharmGKB
CLINDAMYCIN HLA-B

Interaction Score: 1.65

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27527109

Sources:
PharmGKB
DAPSONE HLA-B

Interaction Score: 1.48

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29512326 29458119 28885988 24152261 23604100

Sources:
PharmGKB
CARBIMAZOLE HLA-B

Interaction Score: 1.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26599303 26151496

Sources:
PharmGKB
CLAVULANIC ACID HLA-B

Interaction Score: 0.71

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30664875

Sources:
PharmGKB
ACETAZOLAMIDE HLA-B

Interaction Score: 0.45

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21342230

Sources:
PharmGKB
ABACAVIR HLA-B

Interaction Score: 0.45

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19629158

Sources:
FDA
METHIMAZOLE HLA-B

Interaction Score: 0.41

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26599303 26151496

Sources:
PharmGKB
BCG VACCINE HLA-B

Interaction Score: 0.41

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17028812

Sources:
NCI
TICLOPIDINE HLA-B

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17339877

Sources:
PharmGKB
MINOCYCLINE HLA-B

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
AMOXICILLIN HLA-B

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30664875

Sources:
PharmGKB
RIBAVIRIN HLA-B

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12873589 23360626

Sources:
PharmGKB
SULFASALAZINE HLA-B

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25303297

Sources:
PharmGKB
PAZOPANIB HLA-B

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26546620

Sources:
PharmGKB FDA
STAVUDINE HLA-B

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CLOZAPINE HLA-B

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9587740 26876947 2222133

Sources:
PharmGKB
CARBAMAZEPINE HLA-B

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16981842

Sources:
NCI FDA
THALIDOMIDE HLA-B

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7876469

Sources:
NCI
OXCARBAZEPINE HLA-B

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
FDA
LAMIVUDINE HLA-B

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PHENYTOIN HLA-B

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
FDA

Ensembl: ENSG00000234745
- Version: 101_38
Alternate Names:

HLA-B Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:

PharmGKB: HLA-B

Version: 18-August-2020

Alternate Names:

PA35056 PharmGKB ID

Gene Info:

Publications:

Cheung CL et al., 2016, HLA-B*38:02:01 predicts carbimazole/methimazole-induced agranulocytosis., Clin Pharmacol Ther

Chen PL et al., 2015, Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study., Nat Commun

Cirulli ET et al., 2019, A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury., Gastroenterology

NCI: HLA-B

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Murata et al., 2004, Reiter's syndrome following intravesical bacille biliE de Calmette-GuErin treatment for superficial bladder carcinoma: report of six cases., Mod Rheumatol

Schmidt et al., 1993, Differential regulation of human leukocyte antigen class I genes by interferon in vivo and in vitro., J Immunother Emphasis Tumor Immunol

Marincola et al., 1994, Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines., J Immunother Emphasis Tumor Immunol

HingoraniCasas: ENSG00000234745
- Version: 31-May-2017
Alternate Names:

ENSG00000234745 Gene Symbol

HLA-B Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
GO: HLA-B
- Version: 01-February-2022
Alternate Names:

HLAB GO Gene Synonym

Gene Info:

Gene Categories:

CELL SURFACE

Publications:
Tempus: HLA-B
- Version: 11-November-2018
Alternate Names:

HLA-B Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
TTD: HLA class I antigen B-7
- Version: 2020.06.01
Alternate Names:

HLA-B TTD Gene Abbreviation

T47415 TTD Target ID

Gene Info:

Publications:
FDA: HLA-B
- Version: 04-September-2020
Alternate Names:

Gene Info:

Publications:

HLA-B Gene Record

HLA-B 3106 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30664875 18256392 24731753 23596311 23291545 23132554 23032409 19696695 19483685 18637831

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30242287 25970075 25918017 20504258 9109770

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27527109

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29512326 29458119 28885988 24152261 23604100

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26599303 26151496

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30664875

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21342230

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19629158

Sources: FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26599303 26151496

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17028812

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17339877

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30664875

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12873589 23360626

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25303297

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26546620

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

n/a

PMIDs:
30664875 18256392 24731753 23596311 23291545 23132554 23032409 19696695 19483685 18637831

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
30242287 25970075 25918017 20504258 9109770

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27527109

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29512326 29458119 28885988 24152261 23604100

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26599303 26151496

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
30664875

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21342230

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
19629158

Sources:
FDA

Interaction Types & Directionality:

n/a

PMIDs:
26599303 26151496

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17028812

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17339877

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
30664875

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12873589 23360626

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25303297

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26546620

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
9587740 26876947 2222133

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16981842

Sources:
NCI FDA

Interaction Types & Directionality:

n/a

PMIDs:
7876469

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
FDA

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
FDA

Alternate Names:

HLA-B Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Alternate Names:

PA35056 PharmGKB ID

Alternate Names:

ENSG00000234745 Gene Symbol

HLA-B Ensembl Id

Gene Categories:

DRUGGABLE GENOME